S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
NASDAQ:BXRX

Baudax Bio (BXRX) Stock Price, News & Analysis

$0.02
+0.00 (+7.39%)
(As of 02/29/2024)
Today's Range
$0.02
$0.02
50-Day Range
$0.02
$0.03
52-Week Range
$0.01
$3.47
Volume
310,800 shs
Average Volume
281,029 shs
Market Capitalization
$1.14 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
BXRX stock logo

About Baudax Bio Stock (NASDAQ:BXRX)

Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care related settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with other non-NSAID analgesics. It also develops BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMB, which is in phase I clinical trial, as well as a proprietary blockade reversal agent; and BX3000, a NMB reversal agent that is in preclinical studies. Baudax Bio, Inc. was incorporated in 2019 and is based in Malvern, Pennsylvania.

BXRX Stock Price History

BXRX Stock News Headlines

Baudax Bio Announces Corporate Update
SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
Why Is Baudax Bio (BXRX) Stock Up 75% Today?
Grab Your Free Bitcoin Today!
And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.
Why Is Baudax Bio (BXRX) Stock Up 130% Today?
Baudax Bio (BXRX) Gets a Hold from Noble Financial
Noble Financial Sticks to Their Hold Rating for Baudax Bio (BXRX)
Baudax Improves on Q1 Results
Recap: Baudax Bio Q1 Earnings
Why Is Baudax Bio (BXRX) Stock Down 52% Today?
See More Headlines
Receive BXRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Baudax Bio and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/16/2023
Today
3/29/2024
Next Earnings (Estimated)
5/10/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:BXRX
Employees
9
Year Founded
N/A

Profitability

Net Income
$-58,790,000.00
Pretax Margin
-18,950.64%

Debt

Sales & Book Value

Annual Sales
$1.27 million
Book Value
($14.93) per share

Miscellaneous

Free Float
52,408,000
Market Cap
$1.14 million
Optionable
Not Optionable
Beta
1.57
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Key Executives

  • Dr. Geraldine A. Henwood Ph.D. (Age 72)
    President, CEO & Director
    Comp: $633.25k
  • Mike Choi
    Vice President of Financial Planning & Analysis
  • Ms. Natalie McAndrew (Age 53)
    Consultant & Principle Accounting Officer
  • Dr. Chan Kim Yong Ph.D. (Age 50)
    Chief Scientific Officer & Director

BXRX Stock Analysis - Frequently Asked Questions

How have BXRX shares performed in 2024?

Baudax Bio's stock was trading at $0.0220 at the beginning of the year. Since then, BXRX stock has decreased by 0.9% and is now trading at $0.0218.
View the best growth stocks for 2024 here
.

When is Baudax Bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024.
View our BXRX earnings forecast
.

How were Baudax Bio's earnings last quarter?

Baudax Bio, Inc. (NASDAQ:BXRX) released its quarterly earnings data on Wednesday, August, 16th. The company reported ($1.49) earnings per share for the quarter, beating analysts' consensus estimates of ($2.04) by $0.55.

When did Baudax Bio's stock split?

Baudax Bio's stock reverse split on the morning of Wednesday, November 30th 2022. The 1-40 reverse split was announced on Wednesday, November 30th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, November 30th 2022. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

What other stocks do shareholders of Baudax Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Baudax Bio investors own include Sorrento Therapeutics (SRNE), Coty (COTY), NIO (NIO), VBI Vaccines (VBIV), ADMA Biologics (ADMA), Energy Transfer (ET), Remark (MARK), Designer Brands (DBI), Geron (GERN) and Matinas BioPharma (MTNB).

Who are Baudax Bio's major shareholders?

Baudax Bio's stock is owned by many different retail and institutional investors. Top institutional investors include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Arnold M Baskies, Geraldine Henwood, Richard S Casten and Winston J Churchill.
View institutional ownership trends
.

How do I buy shares of Baudax Bio?

Shares of BXRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:BXRX) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners